T1	intervention 22 109	tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy
T2	eligibility 497 529	Patients with early breast cance
T3	outcome-Measure 993 1029	distant disease-free survival (DDFS)
T5	total-participants 1050 1054	1535
T6	total-participants 1074 1078	1052
T7	intervention-participants 1125 1128	524
T8	control-participants 1151 1154	528
T9	outcome 1321 1333	10-year DDFS
T10	iv-bin-percent 1335 1338	79%
T11	cv-bin-percent 1343 1346	77%
T14	outcome 1384 1386	OS
T15	iv-bin-percent 1388 1391	82%
T16	cv-bin-percent 1396 1399	78%
T19	outcome 1515 1519	DDFS
T20	iv-bin-percent 1520 1523	79%
T21	iv-bin-percent 1531 1534	82%
T22	outcome 1528 1530	OS
T4	control 871 885	6 standard FEC
